$NOVO B #Novo Nordisk A/S B Novo Nordisk : Semglutide in obesity: a well-managed programme: &gt;Finalisation of the phase III programme - In barely a month, Novo Nordisk has published all of the top line results from the four phase 3 studies… https://t.co/YDJ2uhuSx5 #equity #stocks https://t.co/PcLM5rKHpy